Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma

Keyphrases

• Dose-escalation Study 100%
• Metastatic Melanoma 100%
• Pegylated Interferon 100%
• Ropeginterferon alfa-2b 100%
• Partial Response 83%
• Complete Response 83%
• Adverse Events 33%
• Tolerability 33%
• Response Rate 33%
• Once-weekly 33%
• Disease Progression 16%
• Between-group 16%
• Maintenance Therapy 16%
• Tumor Survival 16%
• High Dose 16%
• Nausea 16%
• Dose Adjustment 16%
• Tumor Response 16%
• Low Toxicity 16%
• Duration of Response 16%
• Pyrexia 16%
• Overall Median Survival 16%
• American Joint Committee on Cancer Staging System 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanoma 100%
• Polyethylene Glycol 100%
• Peginterferon Alpha2a 100%
• Tolerability 40%
• Adverse Event 40%
• Neoplasm 20%
• Disease Exacerbation 20%
• Nausea 20%
• Metastatic Melanoma 20%
• Fever 20%
• Cancer Staging 20%
• Peginterferon 20%